Investor News
TR-1: Standard form for notification of major holdings
For full details click here Enquiries: investors.medaphor.com/advisors
Director/PDMR shareholding
Further to the announcement made on 8 October 2018, MedaPhor Group plc (AIM: MED), the intelligent ultrasound software and simulation company, announces that Andrew Barker, Non-Executive Director of the Company, has been issued 66,781 new ordinary shares of 1 pence each in the capital of the Company (“Ordinary Shares”) pursuant to the completion of the acquisition of Intelligent Ultrasound Limited, which was originally announced on 19 September 2017. Following this issue, Mr. Barker has an interest in 200,344 Ordinary Shares representing approximately 0.2 per cent. of the Company's issued ordinary share capital.
Payment of deferred consideration
On 6 October 2017, MedaPhor Group plc (AIM: MED), the intelligent ultrasound software and simulation company, announced completion of the acquisition of Intelligent Ultrasound Limited ("IUL") (the “Acquisition”) pursuant to a sale and purchase agreement (the “IUL SPA”). In accordance with the terms of the IUL SPA, 6,175,975 new ordinary shares of 1p each in the Company (“Ordinary Shares”) (“the Retention Shares”) and a new warrant certificate representing rights to subscribe for 418,897 new Ordinary Shares (“the Retention Warrants”) are being issued to the vendors of IUL (“Vendors”). The issue of the Retention Shares and the Retention Warrants was, under the [...]
Medaphor featured in the silicon review’s 30 fastest growing tech companies 2018
MedaPhor Group plc has been named as one of the 30 Fastest Growing Tech Companies 2018 by US business magazine, The Silicon Review. To mark the listing, the magazine has published an exclusive interview with MedaPhor’s CEO Stuart Gall, who discusses the company’s business divisions, gold-standard product portfolio and his vision for the future of ultrasound. We’re in a highly competitive market, but we have always set ourselves the target of being recognized as the gold standard in terms of product performance.
Half yearly report
MedaPhor Group plc (AIM: MED), the intelligent ultrasound software and simulation company, announces its unaudited half year results to 30 June 2018. Highlights Simulation division sales increased 23% on the comparative period to £2.5m (H1 2017: £2.1m) Strong revenue contribution from the newly launched BodyWorks Eve driven by high uptake from our reseller network Intelligent Ultrasound successfully integrated into the Group and new Clinical software division created ScanNav artificial intelligence (AI) ultrasound peer review pilots commenced in two UK hospitals NeedleGuide AI software development commenced Cash balance at 30 June 2018 of £2.5m (31 December 2017: £4.3m) Commenting on the […]
Medaphor expands ScanNav AI pilot
MedaPhor Group plc (AIM: MED), the intelligent ultrasound software and simulation company, announces that it has expanded the pilot of its ScanNav artificial intelligence (“AI”) image analysis software into its second UK hospital, at the Princess Anne Wing Ultrasound Department of the Royal United Hospitals (“RUH”), Bath. ScanNav is the first CE marked AI system to carry out an automated, real-time “peer review” of obstetric ultrasound images as the patient is scanned. Initially targeted at the UK pregnancy screening programme, offered to all women at approximately 20 weeks of pregnancy, ScanNav uses deep-learning to evaluate over 50 individual criteria to [...]
ScanTrainer installed at Central Middlesex Hospital
MedaPhor Group plc (AIM: MED), the intelligent ultrasound software and simulation company, announces that ScanTrainer, the OBGYN and General Medical simulator training platform, has been installed at a new Ultrasound Training Academy at Central Middlesex Hospital, London, UK. The London North West Healthcare NHS Trust (LNWH) has chosen ScanTrainer for its new state-of-the-art ultrasound education facility based at Central Middlesex Hospital. The Academy has been designed to ease growing ultrasound training pressures and clinical demands across the Trust and beyond. Following an assessment of the ultrasound simulation market, the Trust purchased a ScanTrainer Transvaginal Simulator (TVS) and a ScanTrainer Transabdominal Simulator (TAS) [...]
Grant of options
MedaPhor Group plc (AIM: MED), the intelligent ultrasound software and simulation company, announces that the following additional share options over the Ordinary Shares of the Company have been granted to the Executive Directors. In respect of each director's share options set out above, one third of the above share options will vest once the closing mid-market price of the Company's Ordinary Shares reaches an average of least 25p per share for a continuous period of 20 business days; one third of the share options will vest once the closing mid-market price of the Company's Ordinary Shares reaches an average of at [...]
First BodyWorks Eve installed at NYU School of Medicine
MedaPhor, the intelligent ultrasound software and simulation company, announces that it has installed its first BodyWorks Eve, Point of Care ultrasound (PoCUS) simulator, at NYU School of Medicine, in the simulation laboratory of the affiliated Veterans Affairs New York Harbor Healthcare System NY Campus, New York, USA. BodyWorks Eve is an ultra-realistic female manikin-based simulator designed specifically for doctors looking to train in Point of Care Ultrasound (PoCUS)and will aid the teaching of PoCUS to medical students, residents and faculty. Complete with over 100 real patient scans and over 10,000 pathology variations across cardiac, lung, transabdominal and pelvic ultrasound, it is [...]
AGM statement
MedaPhor Group plc (AIM: MED), the intelligent ultrasound software and simulation company, will hold its Annual General Meeting today at 10.30 a.m. at IP Group Offices, The Walbrook Building, 25 Walbrook, London, EC4N 8AF. At the meeting the Chairman, Riccardo Pigliucci, will make the following statement: “The Group is trading in line with management’s expectations, research and development work being undertaken by our Clinical Division is progressing well and Simulation Division sales in the UK and mainland Europe are showing good signs of recovery. Initial orders placed in our key territories for our recently launched BodyWorks point of care and [...]